

・ 刊行物一覽

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hirayama K, Kobayashi M, Usui J, Arimura Y, Sugiyama H, Nitta K, Muso E, Wada T, Matsuo S and Yamagata K on behalf of the Japanese RPGN Study Group of Progressive Renal Disease	Pulmonary involvements of anti-neutrophil cyto-plasmic autoantibody-associated renal vasculitis in Japan.	Nephrol Dial Transplant(2015)	30	i83-i93	2015
有村義宏	好酸球性多発血管炎性肉芽腫症	科学評論社	63(3)	239-245	2015
有村義宏	ANCA 関連血管炎. ANCA 関連血管炎	呼吸器内科	27(4):	287-292	2015
有村義宏	好酸球性多発血管炎性肉芽腫症	診断と治療	103(5)	649-654	2015
有村義宏	好酸球浸潤と膠原病.-好酸球性多発血管炎性肉芽腫症を含む.	成人病と生活習慣病	45(7)	857-863	2015
有村義宏	血管炎症候群	リウマチ科	54(1)	31-41	2015
有村義宏	血管炎症候群	炎症と免疫	23(6)	32-36	2015
有村義宏	顕微鏡的多発血管炎. 免疫症候群(第2版) その他の免疫疾患を含めて.	別冊 日本臨床	34	777-783	2015
Tezuka D, Haraguchi G, Inagaki H, Isobe M	Progression of thrombogenesis in large coronary aneurysms during anticoagulant therapy in a Buerger's disease patient.	BMJ Case Reports	10	9945	2013
Kato Y, Terashima M, Ohigashi H, Tezuka D, Ashikaga T, Hirao K, Isobe M	Vessel Wall Inflammation of Takayasu Arteritis Detected by Contrast-enhanced Magnetic Resonance Imaging: Association with Disease Distribution and Activity.	Plos One		publisehd on line	2015

Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayama S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F	Takayasu arteritis and ulcerative colitis -high concurrence ratio and genetic overlap.	Arthritis Rheum	67	2226-2232	2015
Matsumura T, Amiya E, Tamura N, Maejima Y, Komuro I, Isobe M	A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity.	Heart Vessels	publisehd on line		2015
磯部光章	高安動脈炎の新しい診断法と治療法	Medical Asahi	1月号	27-29	2016
手塚大介、磯部光章	高安動脈炎	Heart View	11月増刊	70-73	2015
Yoshiko Watanabe, Tetsuro Miyata, Kazuo Tanemoto	Current Clinical Features of New Patients with Takayasu Arteritis Observed From a Cross-Country Research in Japan : Age and Sex Specificity.	Circulation.	132 (18)	1701-1709	2015 Nov
Yabumoto C, Akazawa H, Yamamoto R, Yano M, Kudo-Sakamoto Y, Sumida T, Kamo T, Yagi H, Shimizu Y, Saga-Kamo A, Naito AT, Oka T, Lee JK, Suzuki J, Sakata Y, Uejima E, Komuro I.	Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression.	Sci Rep	25	14453	2015

Sumida T, Naito AT, Nomura S, Nakagawa A, Higo T, Hashimoto A, Okada K, Sakai T, Ito M, Yamaguchi T, Oka T, Akazawa H, Lee JK, Minamino T, Offermanns S, Noda T, Botto M, Kobayashi Y, Morita H, Manabe I, Nagai T, Shiojima I, Komuro I.	Complement C1q-induced activation of β -catenin signalling causes hypertensive arterial remodelling.	Nat Commun	26	6241	2015
Nakayama A, Morita H, Hayashi N, Nomura Y, Hoshina K, Shigematsu K, Ohtsu H, Miyata T, Komuro I	Inverse Correlation Between Calcium Accumulation and the Expansion Rate of Abdominal Aortic Aneurysms.	Cir J	in press		2015
Katagiri M, Takahashi M, Doi K, Myojo M, Kiyosue A, Ando J, Hirata Y, Komuro I.	Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease	Heart Vessels	in press		2015
Yamaguchi T, Amiya E, Watanabe M, Komuro I.	Improvement of Severe Heart Failure after Endovascular Stent Grafting for Thoracic Aortic Aneurysm	Int Heart J	56	682-5	2015
Fujita D, Takeda N, Morita H, Kato M, Nishimura H, Inuzuka R, Taniguchi Y, Nawata K, Hyodo H, Imai Y, Hirata Y, Komuro I.	A novel mutation of TGFBR2 causing Loays-Dietz syndrome complicated with pregnancy-related fatal cervical arterial dissections	Int J Cardiol	201	288-90	2015
Takata M, Amiya E, Watanabe M, Yamada N, Watanabe A, Kawarasaki S, Ozeki A, Nakao T, Hosoya Y, Ando J, Komuro I	The association between orthostatic increase in pulse pressure and ischemic heart disease	Clin Exp Hypertens	in press		2015

Ito M, Doi K, Takahashi M, Koyama K, Myojo M, Hosoya Y, Kiyosue A, Ando J, Noiri E, Yahagi N, Hirata Y, Komuro I.	Plasma neutrophil gelatinase-associated lipocalin predicts major adverse cardiovascular events after cardiac care unit discharge.	J Cardiol.	67	184-91	2015
Sakamoto A, Ishizaka N, Imai Y, Uehara M, Ando J, Nagai R, Komuro I.	Relationship between serum IgG4 concentrations and atherosclerotic coronary plaques assessed by computed tomographic angiography.	J Cardiol	in press		2015
Imai Y, Morita H, Takeda N, Miya F, Hyodo H, Fujita D, Tajima T, Tsunoda T, Nagai R, Kubo M, Komuro I	A deletion mutation in myosin heavy chain 11 causing familial thoracic aortic dissection in two Japanese pedigrees	Int J Cardiol.	195	290-2	2015
Takeda N, Morita H, Fujita D, Inuzuka R, Taniguchi Y, Imai Y, Hirata Y, Komuro I.	Congenital contractural arachnodactyly complicated with aortic dilatation and dissection: Case report and review of literature.	Am J Med Genet A	167	Jul-82	2015
Matsumura T, Amiya E, Tamura N, Maejima Y, Komuro I, Isobe M.	A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity.	Heart Vessels.	in press		2015
Myojo M, Takahashi M, Tanaka T, Higashikuni Y, Kiyosue A, Ando J, Fujita H, Komuro I, Hirata Y.	Midterm follow-up after retrievable inferior vena cava filter placement in venous thromboembolism patients with or without malignancy.	Clin Cardiol	38	216-21	2015
Arita Y, Nakaoka Y, Otsuki M, Higuchi K, Hashimoto-Kataoka T, Yasui T, Masaki T, Ohtani T, Kishimoto T, Yamauchi-Takahara K, Komuro I, Sakata Y.	Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis.	Int J Cardiol.	187	319-321	2015

Cherif M., Caputo M, Nakaoka Y, Angelini G, Ghorbel M.	Gab1 Is Modulated by Chronic Hypoxia in Children with Cyanotic Congenital Heart Defect and Its Overexpression Reduces Apoptosis in Rat Neonatal Cardiomyocytes.	BioMed Research International.	Article ID 718492 (8 pages)	http://dx.doi.org/10.1155/2015/718492	2015
Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takahara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y.*	Interleukin-6/interleukin-21-signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.	Proc Natl Acad Sci U S A.	112(20)	E2677-86. doi: 10.1073/pnas.1424774112.	2015
Terao C, Matsumura T, Yoshifuji H, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayama S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Omura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F.	Takayasu arteritis and ulcerative colitis-high concurrence ratio and genetic overlap.	Arthritis & Rheumatol.	67(8)	2226-2232	2015
Kizu T, Yoshida Y, Furuta K, Ogura S, Egawa M, Chatani N, Hamano M, Takemura T, Ezaki H, Kamada Y, Nishida K, Nakaoka Y, Kiso S, Takehara T.	Loss of Gab1 adaptor protein in hepatocytes aggravates experimental liver fibrosis in mice.	Am J Physiol Gastrointest Liver Physiol.	308(7)	G613-24	, 2015. doi: 10.1152/ajpgi.00289.2014
中岡良和.	IL-6による肺高血圧症の病態形成の分子機構.	Pulmonary Hypertension Update .	1	62-67	2015

Onishi S, Adnan E, Ishizaki J, Miyazaki T, Tanaka Y, Matsumoto T, Suemori K, Shudou M, Okura T, Takeda H, Sawasaki T, Yasukawa M, Hasegawa H.	Novel Autoantigens Associated with Lupus Nephritis.	PLoS One	10(6)	e0126564	2015
Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y.	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus	Rheumatology (Oxford)	54(3)	405-12	2015
Suemori K, Miyamoto H, Murakami S, Yamazaki H, Ishizaki J, Matsumoto T, Murakami Y, Hasegawa H, Yasukawa M.	Pulmonary Nocardiosis due to Nocardia asiatica in a Patient with ANCA-associated Vasculitis	Kansenshogaku Zasshi	89(4)	470-5	2015
Suemori K, Hasegawa H, Ishizaki J, Matsumoto T, Onishi S, Sada E, Sugita A, Yasukawa M.	Methotrexate-associated Lymphoproliferative Disease with Multiple Pulmonary Nodules in a Patient with Rheumatoid Arthritis	Intern Med	54(11)	1421-5	2015
Arita Y, Nakaoka Y, Otsuki M, Higuchi K, Hashimoto-Kataoka T, Yasui T, Masaki T, Ohtani T, Kishimoto T, Yamauchi-Takihara K, Komuro I, Sakata Y.	Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis.	Int J Cardiol.	187	319-321	2015
Cherif M., Caputo M, Nakaoka Y, Angelini G, Ghorbel M.	Gab1 Is Modulated by Chronic Hypoxia in Children with Cyanotic Congenital Heart Defect and Its Overexpression Reduces Apoptosis in Rat Neonatal Cardiomyocytes.	BioMed Research International.	Article ID 718492 (8 pages)	http://dx.doi.org/10.1155/2015/718492	2015

Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takahara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y.*	Interleukin-6/interleukin-21-signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.	Proc Natl Acad Sci U S A.	112(20)	E2677-86. doi: 10.1073/pnas.1424774112.	2015
Terao C, Matsumura T, Yoshifuji H, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayama S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Omura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F.	Takayasu arteritis and ulcerative colitis-high concurrence ratio and genetic overlap.	Arthritis & Rheumatol.	67(8)	2226-2232	2015
Kizu T, Yoshida Y, Furuta K, Ogura S, Egawa M, Chatani N, Hamano M, Takemura T, Ezaki H, Kamada Y, Nishida K, Nakaoka Y, Kiso S, Takehara T.	Loss of Gab1 adaptor protein in hepatocytes aggravates experimental liver fibrosis in mice.	Am J Physiol Gastrointest Liver Physiol.	308(7)	G613-24	, 2015. doi: 10.1152/ajpgi.00289.2014.
中岡良和.	IL-6による肺高血圧症の病態形成の分子機構.	Pulmonary Hypertension Update .	1	62-67	2015
Oh K, Ito S, Unno M, Kobayashi D, Azuma C, Abe A, Otani H, Ishikawa H, Nakazono K, Narita I, Murasawa A.	Decrease in disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate.	Intern Med	54	1035-1041	2015

Shimada A, Kobayashi T, Ito S, Okada M, Murasawa A, Nakazono K, Yoshie H.	Expression of anti-Porphyrromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.	J Periodont Res		doi:10.1111/jre.12288	2015
Kojima A, Kobayashi T, Ito S, Murasawa A, Nakazono K, Yoshie H.	Tumor necrosis factor-alpha gene promoter methylation in Japanese adults with chronic periodontitis and rheumatoid arthritis.	J Periodont Res		doi:10.1111/jre.12314	2015
Hirose T, Saiki R, Uemura T, Suzuki T, Dohmae N, Ito S, Takahashi H, Ishii I, Toida T, Kashiwagi K, and Igarashi K.	Increase in acrolein-conjugated immunoglobulins in saliva from patients with primary Sjögren's syndrome.	Clin Chim Acta	450	184-189	2015
Kobayashi T, Ito S, Kobayashi D, Kojima A, Shimada A, Narita I, Murasawa A, Nakazono K, Yoshie H.	Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors.	Clin Exp Dental Res			in press
伊藤 聡、小林大介、成田一衛、小林哲夫、吉江弘正、村澤 章、中園 清	当院における生物学的製剤使用時の感染症対策について トシリズマブ使用患者の選定、指導、連携を中心にー	リウマチ科	53	99-104	2015
伊藤 聡	当科におけるリウマチ・膠原病患者でのトラマドール塩酸塩/アセトアミノフェン配合錠(トラムセット®配合錠)の使用経験	リウマチ科	53	317-326	2015

伊藤 聡、小林大介、石川 肇、村澤章、成田一衛、中園 清	関節リウマチの、実臨床における treat to target (T2T) 当院看護師、理学療法士の発らー	リウマチ科	54	349-357	2015
伊藤 聡、小林大介、児玉 暁、親川知、針金健吾、阿部麻美、大谷 博、石川肇、村澤 章、成田一衛、中園 清	当院の関節リウマチ患者における etanercept から tocilizumab の切り替えについて - 切り替え時における prednisolone (PSL)増量の影響	リウマチ科	54	567-574	2015
Sada KE, Yamamura M, Harigai M, Fujii T, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.	Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria.	Mod Rheumatol.	25	657-9	2015
Katsuyama T, Sada KE, Namba S, Watanabe H, Katsuyama E, Yamanari T, Wada J, Makino H.	Risk factors for the development of glucocorticoid-induced diabetes mellitus.	Diabetes Res Clin Pract.	108	273-9	2015
Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.	Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.	Arthritis Research & Therapy	17	305	2015

勝山恵理、佐田憲映	【高齢者のリウマチ性疾患-診断や治療における注意点】顕微鏡的多発血管炎	リウマチ科	53	1-5	2015
勝山隆行、佐田憲映	新しい血管炎の概念と分類	臨床免疫・アレルギー科	63	610-615	2015
佐田 憲映, 榎野 博史	【血管炎】わが国の血管炎の現状と今後の展望	日本腎臓学会誌	56	65-69	2015
渡辺 晴樹, 佐田 憲映	【リウマチ医に必要な消化器疾患の最新知識】血管炎に伴う虚血性腸炎	リウマチ科	53	436-440	2015
Katsumata Y, Kawaguchi Y, Yamanaka H.	Interstitial Lung Disease with ANCA-associated Vasculitis.	Clin Med Insights Circ Respir Pulm Med.	9	Jun-51	2015
Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.	Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.	Arthritis Res Ther.	17	305	2015
Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiwara H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group.	Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study.	J Rheumatol.	42	614-622	2015

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M.	Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.	Mod Rheumatol.	4	609-614	2015
Sada KE, Yamamura M, Harigai M, Fujii T, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.	Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria.	Mod Rheumatol.	4	657-659	2015
Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, Arimura Y, Makino H	Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.	Arthritis Res Ther	16(2)	R101	2014
土橋 浩章	エビデンスに基づく急速進行性腎炎症候群(RPGN)診療ガイドライン 2014	日本腎臓学会誌	57 巻 1 号	P139-232	2014
土橋 浩章	ANCA 関連血管炎の病因・病理、診断・治療	日本臨床 血管炎	71 巻増刊 1	P381-386	2013

中石浩己, 洲崎賢太郎, 土橋浩章	ANCA の検査法と問題点	臨床検査	57 巻 3 号	P328-334	2013
柴田悠平、堀田哲也、渥美達也	抗リン脂質抗体等における肺血栓塞栓症	血栓と循環	23(2)	186-191	2015
久田諒、堀田哲也、渥美達也	原発性抗リン脂質抗体症候群	リウマチ科	54(1)	14-20	2015
久田諒、堀田哲也	抗リン脂質抗体症候群 - 血栓症の機序について-	リウマチ科	53(3)	260-266	2015
服部敏之、堀田哲也	全身性エリテマトーデス(ループス腎炎)	リウマチ科	54(3)	277-282	2015
大村一将、堀田哲也	RA 以外の膠原病に対する生物学的製剤治療の可能性：全身性エリテマトーデス	炎症と免疫	23(2)	137-141	2015
堀田哲也、渥美達也	原発性抗リン脂質抗体症候群	臨床免疫・アレルギー科	65(1)	15-21	2016
堀田哲也	SLE と抗リン脂質抗体症候群	Monthly Book Derma	235	61-67	2015
保田晋助、堀田哲也	リウマチ性多発筋痛症	日本内科学雑誌	104(10)	2157-2162	2015
Watanabe K, Yasuda S, Noguchi A, Horita T, Atsumi T	Coronary and mesenteric involvement in polyarteritis nodosa	Arthritis Rheumatol.	67(2)	583	2015
Kono M, Yasuda S, Stevens RL, Koide H, Kurita T, Shimizu Y, Kanetsuka Y, Oku K, Bohgaki T, Amengual O, Horita T, Shimizu T, Majima T, Koike T, Atsumi T.	RasGRP4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation	Arthritis Rheumatol.	67(2)	396-407	2015
Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T.	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis	Rheumatology (Oxford)	54(1)	39-44	2015

Fujieda Y, Amengual O, Kono M, Kurita T, Otomo K, Kato M, Oku K, Bohgaki T, Horita T, Yasuda Y, Kuroki K, Maenaka K, Matsumoto M, Hatakeyama S, Atsumi T	Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes	Rheumatology (Oxford)				印刷中
Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, Watanabe T, Bohgaki T, Horita T, Yasuda S, Atsumi T.	Autoantibodies against component 1q subcomponent(C1q), contribute to complement activation and recurrent thrombosis/pregnancy morbidity in antiphospholipid syndrome (APS)	Rheumatology (Oxford)				印刷中
Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S, Atsumi T.	An independent validation of the global anti-phospholipid syndrome score in Japanese cohort of patients with autoimmune diseases	Lupus	24(7)	774-775	2015	
Kataoka H, Yasuda S, Fukaya S, Oku K, Horita T, Atsumi T, Koike T.	Decreased expression of Runx1 and lowered production of Foxp3+ CD25+ CD4+ regulatory T cells in systemic sclerosis	Mod Rheumatol	25(1)	90-95	2015	
Yasuda S, Kurita T, Horita T, Atsumi T	Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis: reply	Rheumatology (Oxford)	54(6)	1129	2015	
Tanimura K, Jin H, Suenaga T, Morikami S, Arase N, Kishida K, Hirayasu K, Kohyama M, Ebina Y, Yasuda S, Horita T, Takasugi K, Ohmura K, Yamamoto K, Katayama I, Sasazuki T, Lanier LL, Atsumi T, Yamada H, Arase H	2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome	Blood	125(18)	2835-2844	2015	

Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F	Takayasu arteritis and ulcerative colitis -high concurrence ratio and genetic overlap	Arthritis Rheumatol.	67(8)	2236-2232	2015
Ganesh Raghu, Bram Rochweg, Yuan Zhang, Carlos A. Cuello Garcia, Arata Azuma, Juergen Behr, Jan L. Brozek, Harold R. Collard, William Cunningham*, Sakae Homma, Takeshi Johkoh, Fernando J. Martinez, Jeffrey Myers, ShandraL.Protzko, Schunemann; on behalf of theATS,ERS,JRS,andALAT.LucaRicheldi, DavidRind, MoisesSelman, ArthurTheodore, AtholU.Wells, HenkHoogsteden, andHolgerJ.	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline	Am J Respir Med	192	e3-e9	2015
Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, Otsuka H, Ishida F, Hirota N, Sano G, Sugino K, Sakamoto S, Takai Y, Shibuya K, Iyoda A, Homma S.	Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.	Cancer Genomics & Proteomics.	12	31-38	2015
Sakamoto S, Muramatsu Y, Sato K, Ishida F, Kikuchi N, Sano G, Sugino K, Isobe K, Homma S	Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A case-control study.	Respirology,	20	445-452	2015

Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S	Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.	Respiration	89	201-207	2015
Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S	A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan	Respiratory Investigation	53	51-59	2015
Keishi Sugino, Yasuhiko Nakamura, Takafumi Ito, Takuma Isshiki, Susumu Sakamoto, Sakae Homma	Comparison of clinical characteristics and outcomes between combined pulmonary fibrosis and emphysema associated with usual interstitial pneumonia pattern and non-usual interstitial pneumonia.	Sarcoidosis Vasc Diffuse Lung Dis,	32	129-137	2015
Junya Tominaga, Fumikazu Sakai, Takeshi Johkoh, Satoshi Noma, Masanori Akira, Kiminori Fujimoto, Thomas V. Colby, Takashi Ogura, Yoshikazu Inoue, Hiroyuki Taniguchi, Sakae Homma, Yoshio Taguchi, Yukihiko Sugiyama	Diagnostic certainty of idiopathic pulmonary fibrosis/usual interstitial pneumonia: The effect of the integrated clinico-radiological assessment	European Journal of Radiology			2015
Isshiki T, Sugino K, Gocho K, Furuya K, Shimizu M, Ohata T, Wada T, Isobe K, Sakamoto S, Takai Y, Homma S	Primary antiphospholipid syndrome associated with diffuse alveolar hemorrhage and pulmonary thromboembolism.	Intern Med	54	2029-2033	2015
杉野圭史、本間 栄	ステロイド、免疫抑制剤使用を巡る経緯とガイドライン。	呼と循	63	117-122	2015
本間 栄、杉山幸比古	特発性肺線維症に対する新規治療薬 低分子チロシンキナーゼ阻害薬ニンテダニブ(BIBF1120)。	日胸	74	198-209	2015

坂本 晋、本間 栄	IPF の治療効果指標.	呼吸器内科	27	104-109	2015
坂本 晋、本間 栄	3つの IPF 治療第 III 相試験が示す	分子呼吸器病	19	37-40	2015
仲村泰彦、杉野圭史、後町杏子、伊豫田明、植草利公、本間 栄	長期経過を追えた濾胞性細気管支炎を合併した関節リウマチの 1 例.	Therapeutic Research	36	555-556	2015
坂本 晋、本間 栄	職業と呼吸器疾患	成人病と生活習慣病	45	773-779	2015
杉野圭史、本間 栄	間質性肺炎 外来での管理法と紹介のタイミング	medicina	52	1562-1564	2015
杉野圭史、本間 栄	拘束性肺疾患に関連する咳。「せき」の鑑別、アプローチ、専門家の診方かた	Mebio	32	53-58	2015
坂本 晋、本間 栄	IPF の難病指定と社会的な問題	The Lung perspectives	23	236-239	2015
坂本 晋、本間 栄	IPF と虚血性心疾患.	呼吸器内科	28	343-346	2015
本間 栄	総括研究報告	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書		p3-16	2015
坂本 晋、杉野圭史、本間 栄	特発性肺線維症の進行防止におけるピルフェニドンおよびピルフェニドン+N-アセチルシステイン (NAC) 吸入併用療法に関する前向き多施設協同研究.	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書		p55-58	2015
大畠孝則、杉野圭史、仲村泰彦、一色琢磨、後町杏子、鍋木教平、磯部和順、本間 栄	CPFE 合併肺癌患者の治療別予後 解析とリスク因子	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書		p 195-199	2015
國保成暁、阿部信二、神尾孝一郎、弦間昭彦、早坂哲、竹内正弘、谷口博之、迎寛、坂東政司、本間 栄、馬場智尚、小倉高志、吾妻安良太	特発性肺線維症の急性増悪患者に対するトレミキシンを用いた血液浄化療法 (PMX 療法) の有効性及び安全性に関する探索的試験 のプロトコール.	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書		p59-64	2015

高橋弘毅、谷口博之、近藤康博、千葉弘文、井上義一、小倉高志、喜舎場朝雄、本間 栄	新重症度分類策定に基づく治療戦略.	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書	p69-72	2015
谷口博之、片岡健介、近藤康博、三嶋理晃、吾妻安良太、坂東政司、井上義一、小倉高志、本間 栄	長期酸素療法導入後の特発性肺線維症患者の予後調査と予後予測因子の前向き検討(本年度進捗)	厚生労働科学研究委託業務難治性疾患 実用化研究事業びまん性肺疾患に対するエビデンスを構築する新規戦略的研究平成 26 年度研究報告書	p179-182	2015
本間 栄	総括研究報告	厚生労働科学研究費補助金難治性疾患 政策研究事業びまん性肺疾患に関する調査研究班平成 26 年度研究報告書	p3-14	2015
後町杏子、杉野圭史、中村泰彦、一色琢磨、渋谷和俊、植草利公、本間 栄	特発性上葉優位型間質性肺炎の臨床的特徴-特発性肺線維症との比較-	厚生労働科学研究費補助金難治性疾患 政策研究事業びまん性肺疾患に関する調査研究班平成 26 年度研究報告書	p145-150	2015
坂東政司、吾妻安良太、本間 栄	IPF 診療ガイドラインの刊行部会	厚生労働科学研究費補助金難治性疾患 政策研究事業びまん性肺疾患に関する調査研究班平成 26 年度研究報告書	p145-150	2015
高橋弘毅、谷口博之、近藤康博、千葉弘文、井上義一、小倉高志、喜舎場朝雄、本間 栄	特発性肺線維症の QOL 改善.	厚生労働科学研究費補助金難治性疾患 政策研究事業びまん性肺疾患に関する調査研究班平成 26 年度研究報告書	p89-92	2015
井上義一、小倉高志、本間 栄、高橋弘毅、杉山幸比古	第 3 回間質性肺炎/肺線維症勉強会報告	厚生労働科学研究費補助金難治性疾患 政策研究事業びまん性肺疾患に関する調査研究班平成 26 年度研究報告書	p93-98	2015
土橋浩章、佐田憲映、本間 栄、針谷正祥、臼井丈一	抗好中球細胞質抗体 (ANCA) 関連血管炎・急速進行性糸球体腎炎の寛解導入治療の現状とその有効性と安全性に関する観察研究	厚生労働科学研究費補助金 難治性疾患克服研究事業 難治性血管炎に関する調査研究 平成 26 年度総括・分担研究報告書	p 71-73	2015
針谷正祥、佐田憲映、土橋浩章、本間 栄、和田隆志	中小型血管炎分科会活動報告	厚生労働科学研究費補助金 難治性疾患克服研究事業 難治性血管炎に関する調査研究 平成 26 年度総括・分担研究報告書	p 56-61	2015
本間 栄、卜部尚久、杉野圭史	次世代シーケンサーによる網羅的遺伝子検出法を用いた ARDS 症例の基礎疾患検索	厚生労働科学研究費補助金 新興・再興感染症に対する革新的医薬品等開発推進研究事業「高病原性鳥インフルエンザの診断・治療に関する国際連携研究」平成 26 年度総括・分担研究報告	p 23-28	2015

廣田 直,磯部和順、杉野圭史,本間 栄	特発性肺線維症における筋線維芽細胞の抗アポトーシス作用とミトコンドリア品質管理について喫煙が及ぼす影響.	平成 26 年度公益財団法人喫煙科学財団 研究年報		p 234-237	2015
Kitagawa K, Furuichi K, Sagara A, Shinozaki Y, Kitajima S, Toyama T, Hara A, Iwata Y, Sakai N, Shimizu M, Kaneko S, Wada T; Kanazawa Study Group for Renal Diseases and Hypertension	Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis.	Clin Exp Nephrol		Epub ahead of print	2015
Sakai N, Wada T	T Helper 2 Cytokine Signaling in Bone Marrow-Derived Fibroblasts: A Target for Renal Fibrosis	J Am Soc Nephrol	26	Aug-96	2015
Hirayama K, Kobayashi M, Usui J, Arimura Y, Sugiyama H, Nitta K, Muso E, Wada T, Matsuo S, Yamagata K	Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan	Nephrol Dial Transplant	Suppl 1	i83-93	2015
Iinuma C, Waki M, Kawakami A, Yamaguchi M, Tomaru U, Sasaki N, Masuda S, Matsui Y, Iwasaki S, Baba T, Kasahara M, Yoshiki T, Paletta D, Herrmann T, Ishizu A.	Establishment of vascular endothelial cell-reactive type II NKT cell clone from rat model of autoimmune vasculitis.	Int Immunol	27(2)	105-114	2015
Ishihara S, Yasuda M, Ishizu A, Ishikawa M, Shirato H, Haga H.	Activating transcription factor 5 enhances radioresistance and malignancy in cancer cell.	Oncotarget	6(7)	4602-4614	2015
Yamada Y, Tomaru U, Ishizu A, Ito T, Kiuchi T, Ono A, Miyajima S, Nagai K, Higashi T, Matsuno Y, Dosaka-Akita H, Nishimura M, Miwa S, Kasahara M.	Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.	Lab Invest	95(6)	625-634	2015

Tomaru U, Tsuji T, Kiuchi S, Ishizu A, Suzuki A, Otsuka N, Ito T, Ikeda H, Fukasawa Y, Kasahara M.	Decreased expression of a thymus-specific proteasome subunit 5t in Down syndrome patients.	Histopathology	67(2)	235-244	2015
Iwasaki S, Suzuki A, Fujisawa T, Sato T, Shirai S, Kamigaki M, Otsuka N, Tomaru U, Ishizu A.	Fatal cardiac small vessel involvement in ANCA-associated vasculitis: an autopsy case report.	Cardiovasc Pathol	24(6)	408-410	2015
Kawakami T, Yoon SY, Takeuchi S, Soma Y, Kuroha S, Yoshida S, Shida H, Nakazawa D, Tomaru U, Ishizu A.	Novel monoclonal antibodies that recognize both rat and mouse phosphatidylserine/prothrombin complexes.	Mod Rheumatol	in press		
Nakazawa D, Shida H, Kusunoki Y, Miyoshi A, Nishio S, Tomaru U, Atsumi T, Ishizu A.	The responses of macrophages in interaction with neutrophils that undergo NETosis.	J Autoimmun	in press		
中沢大悟, 石津明洋.	特集「腎と免疫」 各論「ANCA関連腎炎」.	腎と透析	78(5)	727-732	2015
石津明洋.	特集「膠原病研究アップデート」 . 血管炎症候群 .	アレルギー・免疫	22(12)	1740-1747	2015
志田玄貴, 石津明洋.	特集「ANCA関連血管炎(AAV)」 MPO-ANCAによる血管傷害のメカニズム .	リウマチ科	54(6)	581-585	2015
Onishi S, Adnan E, Ishizaki J, Miyazaki T, Tanaka Y, Matsumoto T, Suemori K, Shudou M, Okura T, Takeda H, Sawasaki T, Yasukawa M, Hasegawa H.	Novel Autoantigens Associated with Lupus Nephritis.	PLoS One.	10(6)	e0126564	2015
Nakata H, Miyazaki T, Iwasaki T, Nakamura A, Kidani T, Sakayama K, Masumoto J, Miura H.	Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.	Oncology reports.	33(4)	1593-1598	2015

Mokuda S, Miyazaki T, Ubara Y, Kanno M, Sugiyama E,	CD1a(+) survivin(+) dendritic cell infiltration in dermal lesions of systemic sclerosis.	Arthritis Res Ther.	17	275	2015
Mokuda S, Miyazaki T, Ito Y, Yamasaki S, Inoue H, Guo Y, Kong WS, Kanno M, Takasugi K, Sugiyama E, Masumoto J.	The proto-oncogene survivin splice variant 2B is induced by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes.	Scientific reports.	5	9795	2015
Kawashima M, Usui T, Okada H, Mori I, Yamauchi M, Ikeda T, Kajita K, Kito Y, Miyazaki T, Fujioka K, Ishizuka T, Morita H.	TAFRO syndrome: 2 cases and review of the literature.	Modern rheumatology	in press		2015
Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, Imai K, Suetsugu A, Takai K, Shimizu M, Moriwaki H.	Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis.	Hepatology Research	in press		2015
Adachi Y, Mizutani Y, Shu E, Kanoh H, Miyazaki T, Seishima M.	Eosinophilic fasciitis associated with myositis.	Case Reports in Dermatology	7(1)	79-83	2015
Tokuzumi M, Fujisawa T, Shu E, Kanoh H, Saigo C, Miyazaki T, Hamaguchi Y, Seishima M.	Anti-SRP Antibody-positive Myopathy with Universal Alopecia and Multiple Vitiligo.	Acta dermato-venereologica.	95(4)	497-498	2015
Kawakami T, Okano T, Takeuchi S, Kimura S, Soma Y	Complete resolution of refractory cutaneous arteritis by intravenous cyclophosphamide pulse therapy	Int J Dermato	54	e323-e325	2015

Kawakami T, Yoon SY, Takeuchi S, Soma Y, Kuroha S, Yoshida S, Shida H, Nakazawa D, Tomaru U, Ishizu A.	Novel monoclonal antibodies that recognize both rat and mouse phosphatidylserine/prothrombin complexes.	Mod Rheumatol	29	1-2	2015
Kawakami T, Takeuchi S, Okano T, Inoue H, Soma Y	Therapeutic effect of autologous platelet-rich plasma on recalcitrant cutaneous ulcers in livedoid vasculopathy.	J Am Acad Dermatol Case Reports	1	310-311	2015
藤本学, 浅野善英, 石井貴之, 小川文秀, 川上民裕, 小寺雅也, 浅井純, 岩田洋平	膠原病・血管炎にともなう皮膚潰瘍の治療アルゴリズム	Monthly Book Derma	226	71-77	2015
川上民裕	「診療の秘訣」皮膚血管炎アルゴリズム “川上アルゴリズム”の原点	Modern Physician	35	351-352	2015
川上民裕	皮膚症状を呈するなじみのない血管炎 なじみのない皮膚疾患を見逃さないコツ	Monthly Book Derma	228	39-46	2015
川上民裕	クリオグロブリン定性試験の方法を教えてください スキルアップのためのQ&A	皮膚アレルギーフロンティア	13	50	2015
川上民裕	若手医師のためのエキスパートセミナー 血管炎 + 論文作成のコツ	日臨皮会誌	32	51-54	2015
川上民裕	血管炎における抗凝固療法	日本医事新報	4747	59-60	2015
川上民裕	採血後の青あざの機序	日本医事新報	4751	63	2015
川上民裕	IgA 血管炎の腎病変（最近の話題）	皮膚病診療	37	641-648	2015
川上民裕	これが血管とリンパ管の像だ！皮膚かたちアトラス	Visual Dermatology	14	1164-1165	2015
川上民裕	皮膚型結節性多発動脈炎 免疫症候群（ ）その他の免疫疾患を含めて	日本臨床	別 34	766-771	2015

川上民裕	IgA 血管炎 (旧名 Henoch-Schönlein 紫斑病) 免疫症候群 () その他の免疫疾患を含め	日本臨床	別 34	799-803	2015
川上民裕	血管炎 全身性強皮症とその鑑別疾患より 早期に正確に診断するために	Visual Dermatology	15	72-73	2016
川上民裕	「私の処方」リウマトイド血管炎 (悪性関節リウマチ)	Modern Physician	36	77	2016
Furukawa H, Oka S, Shimada K, Masuo K, Nakajima F, Funano S, Tanaka Y, Komiya A, Fukui N, Sawasaki T, Tadokoro K, Nose M, Tsuchiya N, Tohma S.	Autoantibody profiles in collagen disease patients with interstitial lung disease (ILD): Antibodies to major histocompatibility complex class I-related chain A (MICA) as markers of ILD.	Biomarker Insights	:10	63-73 doi: 10.4137/ BMIMI.S2 8209.	2015
Tsuchiya N, Ohashi J.	Editorial: Human immune system diversity and its implications in diseases.	J Hum Genet	60(11)	655-656; doi:10.1 038/jhg. 2015.101	2015
Furukawa H, Oka S, Shimada K, Tsuchiya N, Tohma S.	Genetics of interstitial lung disease: Vol de Nuit (Night Flight).	Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine	9(S1)	:1-7 doi: 10.4137/ CCRPRPM. S23283.	2015
土屋尚之	膠原病および類縁疾患のゲノム解析の現況 ~ GWAS および post GWAS ~ .	リウマチ科	54(4)	473-479	2015
土屋尚之、川崎綾、岡笑美、古川宏	リウマチ・膠原病と HLA.	MHC	22(2)	74-83	2015
Fujimoto S, Kobayashi S, Suzuki K	Epidemiology and classification of vasculitis-international comparative study and latest international trend	Nihon Jinzo Gakkai Shi	56	80-86	2014 昨 年度未報 告分

Yumura W, Kobayashi S, Suka M, Hayashi T, Ito S, Nagafuchi H, Yamada H, Ozaki S; JMAAV Study Group.	Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis	Mod Rheumatol	24	304-309	2014 昨年度未報告分
小林 茂人	強直性脊椎炎【脊椎関節炎の病態・診断・治療】	分子リウマチ治療	8	184-190	2015
小林 茂人	【ロコモティブシンドロームのすべて】ロコモティブシンドロームを構成する疾患 関節リウマチとその関連疾患 その他のリウマチ性疾患	日本医師会雑誌	144	S214-S216	2015
小林 茂人, 木田 一成	【高齢者のリウマチ性疾患-診断や治療における注意点】巨細胞性動脈炎	リウマチ科	53	39-46	2015
小林 茂人, 木田 一成	反応性関節炎 (ReA) (ライター症候群)	日本臨床 別冊 新領域別症候群シリーズ No.34 免疫症候群 第2版	34	694-697	2015
立山 香織(大分大学 医学部耳鼻咽喉科・頭頸部外科), 岸部 幹, 森田 由香, 吉田尚弘, 國本 泰臣, 松井 隆道, 坂口 博史, 岡田 昌浩, 渡辺 毅, 稲垣 彰, 小林 茂人, 飯野 ゆき子, 村上 信五, 高橋 晴雄, 東野 哲也, 原淵 保明, 日本耳科学会 ANCA 関連血管炎性中耳炎全国調査ワーキンググループ	発症型別にみた ANCA 関連血管炎 性中耳炎の臨床的特徴と経過	Otology Japan	25	565	2015
土屋 尚之 長谷部 成美, 日高 操希, 佐田 憲映, 小林 茂人, 山田 秀裕, 古川 宏, 山縣 邦弘, 住田 孝之, 宮坂 信之, 當間 重人, 尾崎 承一, 松尾 清一, 橋本 博史, 槇野 博史, 有村 義宏, 針谷 正祥, 川崎 綾	ANCA 関連血管炎の Update 日本人 集団における ANCA 関連血管炎の 遺伝素因	日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集	59 回	222	2015

多田 久里守, 林 絵利, 小笠原 倫大, 山路 健, 田村 直人, 小林 茂人, 井上 久, 高崎 芳成	TNF 阻害薬の変更を行った強直性 脊椎炎患者 4 例の解析	日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集	59 回	369	2015
谷口 義典, 小林 茂人, 公文 義雄, 寺田 典生, 岸本 暢将	脊椎関節炎の Update(診断と治療) 脊椎関節炎の最新治療薬の話題	日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集	59 回	189	2015
岸本 暢将, 小林 茂人, 谷口 義典, 富田 哲也, 岡田 正人	脊椎関節炎の Update(診断と治療) 診断・分類基準の進歩と問題点 誤りやすい症状の注意	日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集	59 回	188	2015
小林 茂人	内科(リウマチ・膠原病)からみた皮膚血管炎・血管障害の臨床	日本皮膚科学会雑誌	125	725	2015
Kuroda Y, Asada R, So K, Yonezawa A, Nankaku M, Mukai K, Ito-Ihara T, Tada H, Yamamoto M, Murayama T, Morita S, Tabata Y, Yokode M, Shimizu A, Matsuda S, Akiyama H.	A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head.	Int Orthop.		[Epub ahead of print]	2015 Dec 29
Kumagai M, Marui A, Tabata Y, Takeda T, Yamamoto M, Yonezawa A, Tanaka S, Yanagi S, Ito-Ihara T, Ikeda T, Murayama T, Teramukai S, Katsura T, Matsubara K, Kawakami K, Yokode M, Shimizu A, Sakata R.	Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.	Heart Vessels.		[Epub ahead of print]	2015 Apr 11.
猪原 登志子, 藤元 昭一, 鈴木 和男, 遠藤 知美, 武曾 恵理	【血管炎症候群とアフェレシス】 ANCA 関連血管炎に対するアフェレシス療法 抗好中球細胞 質抗体関連血管炎に対する血漿 交換療法と国際共同臨床試験 PEXIVAS.	日本アフェレシス学会雑誌	34 巻 2 号	120-125	2015
猪原 登志子	【臨床研究・臨床試験の信頼性確保への取り組み】 人を対象とする医学系研究に関する倫理指針(疫学・臨床研究統合指針)の概要.	薬理と治療	43 巻 Suppl. 1	s11-s21	2015

杉原 毅彦, 伊賀 祥子, 濱野 慶朋, 武村 拓也, 山田 浩和, 新井 富生, 荒木 厚	関節リウマチ,片側性滲出性胸膜炎の治療中に,肺炎で死亡した1例	内科	116 巻 2 号	310-318	2015
瀧川 正紀, 増富 裕文, 島崎 良知, 濱野 慶朋, 石井 敏浩, 森 淑子, 石神 昭人		日本薬学会年会要旨集	135 年会 4	188	2015
濱野 慶朋, 佐野 夏帆, 丸山 直記, 湯村 和子, 鈴木 和男	MPO-ANCA 関連血管炎自然発症モデル SCG/Kj マウスにおける腎炎 関連遺伝子の解析	日本腎臓学会誌	57 巻 3 号	600	2015
濱野 慶朋, 湯村 和子	老年医学からみた透析医療 老年医学のあゆみと現状 サルコペニア/フレイルティと透析医療の今日の問題	臨床透析	31 巻 10 号	1219-1224	2015
Ken-ei Sada, Masahiro Yamamura, Masayoshi Harigai, Takao Fujii, Yoshinari Takasaki, Koichi Amano, Shouichi Fujimoto, Eri Muso, Yohko Murakawa, Yoshihiro Arimura, Hirofumi Makino, and for the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan	Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study	Arthritis Res Ther	17	305	
Motomu Hashimoto, Toru Yamazaki, Masahide Hamaguchi, Takeshi Morimoto, Masashi Yamori, Keita Asai, Yu Isobe, Moritoshi Furu, Hiromu Ito, Takao Fujii, Chikashi Terao, Masato Mori, Takashi Matsuo, Hiroyuki Yoshitomi, Keiichi Yamamoto, Wataru Yamamoto, Kazuhisa Bessho, and Tsuneyo Mimori	Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients	PLoS One	10	e0122121	

川嶋聡子、要 伸也	全身性自己免疫疾患、血管炎症候群：好酸球性多発血管炎性肉芽腫症 in 免疫症候群	日本臨床別冊 新領域別症候群シリーズ 免疫症候群第2版	34	790-794	2015
要 伸也	急速進行性糸球体腎炎と ANCA 関連血管炎の最新治療	医薬ジャーナル	51	81-86	2015
Tokai N, Ogasawara M, Gorai M, Matsuki Y, Yamada Y, Murayama G, Sugisaki N, Nemoto T, Ando S, Minowa K, Kon T, Tada K, Matsushita M, Yamaji K, Tamura N, Makino S, Takasaki Y	Predictive value of bone destruction and duration of clinical remission for subclinical synovitis in rheumatoid arthritis patients.	Mod Rheumatol	25	540-545	2015
Doe K, Nozawa K, Hirai T, Tsushima H, Hayashi E, Hiruma K, Ando S, Nakano S, Kon T, Amano H, Yamaji K, Tamura N, Takasaki Y	Second-to-fourth Digit Ratio in Systemic Lupus Erythematosus.	J Rheumatol	42	826-828	2015
Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I, Takasaki Y	Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis.	Rheumatology	54	1498-1506	2015
Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe S, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyaama H, Hitoshi K, Miyasaka N, Harigai M, for the PREVENT Study Group	Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases:A Large-scale Prospective Cohort Study.	J Rheumatol	42	614-622	2015
Ishiyama K, Yashiro T, Nakano N, Kasakura K, Miura R, Hara M, Kawai F, Maeda K, Tamura N, Okumura K, Ogawa H, Takasaki Y, Nishiyama C	Involvement of PU.1 in NFATc1 promoter function in osteoclast development.	Allergol Int	64	241-247	2015

Honda D, Tsueshita K, Ohsawa I, Miyashita T, Inoshita H, Shimamoto M, Horikoshi S, Motimoto S, Takasaki Y, Tomino Y	Clinical Significance of Renal Interstitial Fibrosis in Patients with Lupus Nephritis.	Juntendo Mde J	61	418-428	2015
Matsuki Y, Atsumi T, Yamaguchi K, Hisano M, Arata N, Oku K, Watanabe N, Sago H, Takasaki Y, Murashima A	Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications.	Mod Rheumatol	25	215-218	2015
Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M	Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.	Mod Rheumatol	25	609-614	2015
Yasuda S, Atsumi T, Shimamura S, Ono K, Hiromura K, Sada K, Mori M, Takei S, Kawaguchi Y, Tamura N, Takasaki Y	Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.	Mod Rheumatol	25	854-857	2015
Hara R, Miyazawa H, Nishimura K, Momoi T, Nozawa T, Kikuchi M, Sakurai N, Kizawa T, Shimamura S, Yasuda S, Hiromura K, Sada KE, Kawaguchi Y, Tamura N, Takei S, Takasaki Y, Atsumi T, Mori M	A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan.	Mod Rheumatol	25	858-864	2015

Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan	Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.	Arthritis Res Ther	17	305	2015
高崎芳成, 松下雅和, 土江健太郎, 蛭間香織, 山田祐介, 野澤和久	SmD ペプチドを抗原として用いた自己抗体測定試薬「エリア SmDp」の臨床的有用性の検討	医学と薬学	72	139-146	2015
高崎芳成	リウマチの注目療法	健康	3	112-114	2015
駒形嘉紀, 有村義宏	RA 以外の膠原病に対する生物学的製剤治療の可能性：血管炎症候群	炎症と免疫	23	153-158	2015
駒形嘉紀, 有村義宏	ANCA 関連血管炎の診療ガイドラインのポイント	Medical Practice	32	1159-1164	2015
駒形嘉紀	AAV の分類と鑑別診断	リウマチ科	54	594-601	2015

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
磯部光章	高安動脈炎	山口徹	今日の治療指針	医学書院	東京	2015	471-472
伊藤 聡	確立した関節リウマチ評価と治療戦略	松本 功、保田晋介、三森経世、桑名正隆	リウマチ・膠原病診療ハイグレード 分子標的/Bio時代のリウマチ・膠原病治療ストラテジー	文光堂		2015	24-32
土橋浩章	血管炎症候群・結節性多発動脈炎	松本功、三森経世、桑名正隆、保田晋助	分子標的/Bio時代のリウマチ・膠原病治療ストラテジー	文光堂	東京	2015	P339-353
土橋浩章	難治性症例に対する新たな治療法	尾崎承一、楨野博史	ANCA 関連血管炎の診療 ガイドライン(2014年改訂版)	難治性血管炎に関する調査研究班、進行性腎障害に関する調査研究班	岡山, 名古屋	2014	P107-110
土橋浩章	難治性症例に対する新たな治療法	尾崎承一、楨野博史、松尾清一	ANCA 関連血管炎の診療 ガイドライン	ANCA 関連血管炎のわが国における治療法の確立のための多施設共同前向き臨床研究班、難治性血管炎に関する調査研究班、進行性腎障害に関する調査研究班	川崎, 岡山, 名古屋	2011	P73-76
堀田哲也	アミロイドーシス	山口徹、北原光男	今日の治療指針 私はこう治療している 2015年版	医学書院	東京	2015	720
堀田哲也	血管炎症候群	医療情報科学研究所	イヤートップICS 2015-	メディックメディア	東京	2015	232-234

堀田哲也	リウマチ性疾患に使用される薬剤、治療法「6. シクロホスファミド」	日本リウマチ財団教育研修委員会、日本リウマチ学会生涯教育委員会	リウマチ学病学テキスト改訂第2版	診断と治療社	東京	2016	511
堀田哲也	リウマチ性疾患に使用される薬剤、治療法「7. その他の免疫抑制剤」	日本リウマチ財団教育研修委員会、日本リウマチ学会生涯教育委員会	リウマチ学病学テキスト改訂第2版	診断と治療社	東京	2016	512-513
堀田哲也	血球貪食症候群の早期診断と治療	山岡邦弘、五野貴久、三森経世、桑名正隆	リウマチ・膠原病ハイグレード リウマチ・膠原病の合併症や諸問題を解く	文光堂	東京	2016	347-359
本間 栄	胸膜炎	福井次矢、高木誠、小室一成 編	2015 今日の治療指針	医学書院	東京	2015	p342-343
本間 栄	特発性間質性肺炎.	泉孝英 編	ガイドライン外来診療 2015	日経メディカル開発	東京	2015	p442-446
杉野 圭史、本間 栄	特発性肺線維症. EBM を活かす	高橋和久、児玉裕三 編	呼吸器診療	メジカルビュー	東京	2015	p276-285
本間 栄		日本呼吸器学会 編	呼吸器専門医テキスト	南江堂	東京	2015	
杉野圭史、本間 栄	Dual Energy CT の気腫合併肺線維症への応用.	杉山幸比古、近藤 丘、中西洋一、奥村明之進、高橋弘毅、一ノ瀬正和、吉野一郎、本間栄、弦間昭彦、池田徳彦、須田隆文、伊達洋至、永安 武、寺田弘司 編	先端医療シリーズ 46 呼吸器疾患診療の最先端	寺田国際事務所/先端医療技術研究所	東京	2015	97-104

本間 栄、杉野圭史、村松陽子、坂本 晋	特発性肺線維症と酸化ストレス。	杉山幸比古、近藤 丘、中西洋一、奥村明之進、高橋弘毅、一ノ瀬正和、吉野一郎、本間栄、弦間昭彦、池田徳彦、須田隆文、伊達洋至、永安 武、寺田弘司 編	先端医療シリーズ 46 呼吸器疾患診療の最先端	寺田国際事務所/先端医療技術研究所	東京	2015	p145-149
杉野 圭史、本間 栄	Stevens-Johnson 症候群発症後に高度の閉塞性換気障害を認めた 27 歳女性	永井厚志編	New 専門医を目指すケース・メソッド・アプローチ 第 3 版 呼吸器疾患	日本医事新報社	大阪	2015	p251-257
杉野 圭史、本間 栄	特発性肺線維症との概念・定義、特発性肺線維症とその周辺	吾妻安良太 企画	診断と治療の ABC	最新医学社	東京	2015	p14-22
坂本 晋、本間 栄	認定基準の変更、特発性肺線維症とその周辺	吾妻安良太 企画	診断と治療の ABC	最新医学社	東京	2015	p249-254.
石津明洋 .	2. 血管	小田義直, 坂元亨宇, 深山正久, 松野吉宏, 森永正二郎, 森谷卓也	組織病理アトラス(第 6 版)	文光堂	東京	2015	543
石津明洋 .	E. 血管炎 6a. ANCA 関連血管炎 総論	日本リウマチ財団 教育研修委員会, 日本リウマチ学会 生涯教育委員会	リウマチ病学テキスト(改訂第 2 版)	診断と治療社	東京	2016	576
川上民裕	Henoch-Schönlein 紫斑(IgA 血管炎)	渡辺晋一・古川福実	皮膚疾患最新の治療 2015 - 2016	南江堂	東京	2015	pp63-64

川上民裕	皮膚動脈炎(旧名 皮膚型結節性多発動脈炎)(壊死性血管炎が皮膚に起こった場合)	永井良三・福井次矢・木村健二郎・上村直実・桑島巖・今井靖・嶋田元・宮地良樹	今日の臨床サポート	エルゼビア・ジャパン	東京	2015	ウェブサイト: http://clinicalsup.jp/jpoc/
川上民裕	小児の抗リン脂質抗体症候群	横関博雄・片山一朗	幼小児によくみられる皮膚疾患アトラス 鑑別と治療のポイント	医薬ジャーナル社	大阪	2015	pp118-119
川上民裕	リペド血管症にワルファリンは有効か?	宮地良樹	EBM 皮膚疾患の治療 up-to-date	中外医学社	東京	2015	pp85-89
川上民裕	ガイドラインを読むシリーズ 皮膚疾患ガイドライン	宮地良樹	ガイドラインを読むシリーズ 皮膚疾患ガイドライン	メディカルレビュー社	東京	2015	pp60 - 69
川上民裕	ベーチェット病の皮膚病変	外園千恵・加藤則人	皮膚科・眼科の連携マニュアル 目のまわりの病気とその治療	学研メディカル秀潤社	東京	2015	pp136-139
川上民裕	凍瘡	福井次矢・高木誠・小室一成	今日の治療指針 2016 年版	今日の治療指針 2016	東京	2016	pp1243-1244
小林茂人	強直性脊椎炎	金澤一郎、永井良三	今日の診断指針	医学書院	東京	2015	1310-1311
小林茂人、木田一成	骨・関節疾患に対する扁桃摘出術の有効性は?	池田勝久、武田憲昭、香取幸夫、原淵保明、丹生健一	EBM 耳鼻咽喉科・頭頸部外科の治療 2015-2016	中外医学社	東京	2015	368-372
濱野慶朋、佐々木裕子	第4章 症例から学ぶ輸液療法とその管理の実際 高齢者の輸液療法と注意点	内田敏也	Medical Practice32 巻臨増刊 病態生理と症例から学ぶ輸液ガイド	文光堂	東京	2015	340-343
鈴木勝也、竹内勤	血管炎症候群	金澤 一郎、永井良三	今日の診断指針第7版	医学書院	東京	2015	1304-1310

藤井 隆夫	血管炎-総論	公益財団法人 日本リウマチ財 団 教育研修委 員会、一般社団 法人 日本リウ マチ学会 生涯 教育委員会	リウマチ病学テキスト 改訂 第2版	診断と治療 社	東京	2016	234-241
藤井 隆夫	混合性結合組織病	松本 功、保田 晋助、三森 経 世、桑名 正隆	リウマチ・膠原病診療ハイ グレード 分子標的/Bio 時 代のリウマチ・膠原病治療 ストラテジー	文光堂	東京	2015	260-270
要 伸也	急速進行性腎炎症候群に対する ステロイド療法のエビデンスは？	川合真一	ステロイドのエビデンス	羊土社	東京	2015	133-135
高崎芳成	全身性エリテマトーデス.	泉孝英編集主 幹	ガイドライン外来診療 2015.	日経メディカ ル開発	東京	2015	506-510
高崎芳成	抗 RNA 抗体 (抗 U1-RNP 抗体)、 抗 Sm 抗体.	三橋知明, 和田 攻, 矢崎義雄, 小池和彦, 小室 一成編	臨床検査ガイド.	文光堂	東京	2015	747-749
高崎芳成	抗核抗体と臨床の関連性.		コンピューター支援型免疫 蛍光顕微鏡システムむよ る FANA 画像テキスト	コスミックコー ポレーション	東京	2015	9-18
高崎芳成	関節リウマチの診断、疾患活動性 の評価、新しい治療目標.	田中良哉編	関節リウマチと骨粗鬆症・ 内科医が実践すべき診断 と治療.	医薬ジャーナ ル	大阪・東京	2015	36-43
高崎芳成	Behcet 病.	金澤一郎、永井 良三総編集	WS	医学書院	S	2015	1314-1317
駒形嘉紀	ANCA 関連血管炎—多発血管炎 性 肉芽腫症(Wegener 肉芽腫症)	日本リウマチ財 団教育研修委 員会・日本リウ マチ学会生涯 教育委員会編	リウマチ病学テキスト改訂 第2版	診断と治療 社	東京	2016	269-272

RAPID COMMUNICATION

Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: **Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria**

Ken-ei Sada¹, Masahiro Yamamura², Masayoshi Harigai³, Takao Fujii⁴, Yoshihiro Arimura⁵, and Hirofumi Makino¹; for the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan

¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Department of Pharmacovigilance and Department of Medicine and Rheumatology, ⁴Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, and ⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

History

Received 6 June 2014

Accepted 6 October 2014

Published online 10 December 2014

Microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA), have been grouped into the antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitides (AAV) that are characterized by necrotizing small-vessel inflammation and high prevalence of ANCA positivity. In 1990, the American College of Rheumatology (ACR) proposed classification criteria for GPA and EGPA [1,2]. In 1994, the Chapel Hill Consensus Conference (CHCC) produced definitions for vasculitis [3]. These criteria and definitions have been used for the entry criteria in clinical trials of AAV patients, but there are some drawbacks. The ACR has not published criteria for MPA, the ACR criteria for EGPA and GPA do not include ANCA positivity, and the CHCC definitions require histological findings. Recently, Watts et al. proposed a new consensus algorithm for the classification of primary systemic vasculitides, including AAV and polyarteritis nodosa (PAN), for epidemiological studies, now known as the European Medicines Agency (EMA) algorithm [4]. In the algorithm, EGPA is first classified using the ACR or Lanham's criteria, followed successively by GPA, MPA, and PAN. GPA is classified by means of the ACR criteria, the CHCC histological definitions, or histology or ANCA positivity plus surrogate clinical markers for GPA. Subsequently, MPA is classified using the clinical and histological features or ANCA positivity plus surrogate clinical markers for renal vasculitis.

The Ministry of Health, Labour and Welfare (MHLW) criteria for the diagnosis of AAV was proposed in 1998 and are now widely used in Japan, but these criteria have never been formally

validated [5] (Supplementary 1 to be found online at <http://informahealthcare.com/doi/abs/10.3109/14397595.2014.982270>).

We previously conducted a nation-wide, prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides (RemIT-JAV) to characterize Japanese patients with AAV, and to evaluate the effectiveness and safety of remission induction therapy for AAV in Japan (UMIN000001648). A total of 156 patients, receiving a diagnosis of active AAV and requiring immunosuppressive treatment based on the discretion of the site investigators, were enrolled in the study. By applying the EMA algorithm, 14, 33, and 78 patients were classified as EGPA, GPA, and MPA, respectively, but 31 patients remained unclassifiable (Supplementary 2 to be found online at <http://informahealthcare.com/doi/abs/10.3109/14397595.2014.982270>) [6].

In the present study, a cohort of patients in the RemIT-JAV study was reclassified according to the MHLW criteria. The MHLW scheme classified 13 patients as definite and 2 patients as probable EGPA, 57 as definite and 91 as probable GPA, and 37 as definite and 84 as probable MPA, respectively (Supplementary 2 to be found online at <http://informahealthcare.com/doi/abs/10.3109/14397595.2014.982270>). When the EMA algorithm was used as a gold standard, the sensitivity, specificity and accuracy of the MHLW definite criteria were 85.7%, 99.2%, and 98.1% for EGPA; 54.5%, 68.3%, and 65.4% for GPA; and 38.5%, 91.0%, and 64.7% for MPA, respectively. These measures of the MHLW probable criteria were 100%, 99.2%, and 99.4% for EGPA; 97.0%, 5.7%, and 25% for GPA; and 91.0%, 35.9% and 63.5% for MPA, respectively (Table 1).

The MHLW definite criteria for GPA showed a lower specificity. Of 57 patients with MHLW-definite GPA, 5, 54, and 9 patients fulfilled the definite criteria (i), (ii), and (iii), respectively, and several patients simultaneously fulfilled two or more of these criteria; 1, 1, and 8 patients fulfilled (i)+ (ii)+ (iii), (i)+ (ii),

Correspondence to: Hirofumi Makino, MD, PhD, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. Tel: + 81-86-235-7235. Fax: + 81-86-222-5214. E-mail: sadakenn@md.okayama-u.ac.jp

Table 1. Classification capabilities of the Ministry of Health, Labour and Welfare (MHLW) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides with the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides (RemIT-JAV) in comparison with the European Medicines Agency (EMA) algorithm.

a) Eosinophilic granulomatosis with polyangiitis (EGPA).

	MHLW-EGPA definite	MHLW-EGPA probable	MHLW-EGPA unclassified	Total
EMA-EGPA (+)	12	2	0	14
EMA-EGPA (–)	1	0	141	142
Total	13	2	141	156

When the EMA algorithm was used as a gold standard, the sensitivity, specificity and accuracy of the MHLW definite criteria were 85.7%, 99.2%, and 98.1%. These measures of the MHLW probable criteria were 100%, 99.2%, and 99.4%.

b) Granulomatosis with polyangiitis (GPA).

	MHLW-GPA definite	MHLW-GPA probable	MHLW-GPA unclassified	Total
EMA-GPA (+)	18	14	1	33
EMA-GPA (–)	39 (EMA-EGPA 1, EMA-MPA 37)	77 (EMA-EGPA 13, EMA-MPA 40)	7	123
Total	57	91	8	156

The sensitivity, specificity and accuracy of the MHLW definite criteria were 54.5%, 68.3%, and 65.4%. These measures of the MHLW probable criteria were 97.0%, 5.7%, and 25%.

c) Microscopic polyangiitis (MPA).

	MHLW-MPA definite	MHLW-MPA probable	MHLW-MPA unclassified	Total
EMA-MPA (+)	30	41	7	78
EMA-MPA (–)	7 (EMA-EGPA 0, EMA-GPA 6)	43 (EMA-EGPA 7, EMA-GPA 10)	28	78
Total	37	84	35	156

The sensitivity, specificity and accuracy of the MHLW definite criteria were 38.5%, 91.0%, and 64.7%. These measures of the MHLW probable criteria were 91.0%, 35.9% and 63.5%.

and (ii) +(iii), respectively. In 39 patients with MHLW-definite GPA who failed to meet the EMA classification for GPA, 3, 33 and 2 patients fulfilled the MHLW GPA definite criteria (i), (ii), and (ii) +(iii), respectively, which indicates that the major disagreement between the two classification methods is due to the MHLW GPA definite criteria (ii) (Supplementary 1 to be found online at <http://informahealthcare.com/doi/abs/10.3109/14397595.2014.982270>). Since “L symptoms” of the MHLW GPA criteria do not include granulomatous inflammation of the respiratory tract or GPA-related pulmonary lesions such as nodules, infiltrations, and cavities, patients with typical MPA who have K symptoms and pauci-immune, crescentic glomerulonephritis could be classified as GPA if “L symptoms”, that is bloody sputa, cough, and dyspnea, are present. Replacement of current “L symptoms” with “granulomatous histology and GPA-related pulmonary manifestations” may improve the diagnostic capability of the MHLW criteria. In 24 patients fulfilling both of the MHLW definite criteria for GPA and MPA, only 4 patients were classified as GPA and 20 patients were classified as MPA by the EMA algorithm. The specificity and accuracy of the MHLW-GPA criteria could be increased by excluding patients with MHLW-definite EGPA and MPA from MHLW-GPA classification (Supplementary 3 to be found online at <http://informahealthcare.com/doi/abs/10.3109/14397595.2014.982270>). These results suggest that introduction of such a hierarchical classification system to the MHLW diagnosis criteria may improve their classification capabilities.

Sensitivity of the MHLW criteria appeared to be limited for MPA. Of 78 patients with EMA-defined MPA, 48 patients did

not satisfy the MHLW definite criteria for MPA. However, 41 of this 48 patient population fulfilled the MHLW probable criteria (ii). On the other hand, additional 43 patients with probable MPA were classified by the criteria (ii). By the EMA algorithm, they were classified as having EMA-EGPA in 7 patients, EMA-GPA in 10 patients, and unclassifiable vasculitis in 26 patients. Of these 43 patients, 1 of 7 EMA-EGPA patients, none of 10 EMA-GPA patients, and 18 of 26 unclassifiable patients had interstitial lung disease (ILD). These findings indicate that exclusion of ILD from major symptoms of the MHLW MPA criteria and transfer of probable criteria (ii) to the definite criteria, or inclusion of ILD in the EMA algorithm could increase the sensitivity of the MHLW definite criteria for MPA. Although ILD is presumably an essential clinical manifestation in Asian AAV patients [6], further investigation is required for determining the significance of ILD in MPA classification. The predominance of MPA and MPO-ANCA positivity in Japanese patients over patients in Europe and the United States also could contribute to the discordance in classifying MPA. The EMA surrogate markers for GPA should be cautiously applied in Japan and other Asian countries, where MPA is more prevalent than GPA [6].

The MHLW diagnostic criteria are established mainly to define patients who can apply for exemption of medical expenses, while the EMA classification algorithm was developed for epidemiological studies. Thereby, it is difficult to compare the utility and superiority of these two methods in AAV classification. Nonetheless, it is considered as important to understand their concordance and discordance when evaluating the evidence from Western countries in comparison with Japanese evidence.

In conclusion, the MHLW definite criteria had a similar sensitivity and specificity for EGPA but showed a lower sensitivity and specificity for GPA and a lower sensitivity for MPA in comparison with the EMEA algorithm, in a cohort of the RemIT-JAV study. A multi-national clinical study is underway to establish new diagnostic and classification criteria for vasculitides [7]. Comparison of the MHLW criteria with international diagnostic criteria will provide important information for future modification of the MHLW criteria.

EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.

Acknowledgements

This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (nannti-ippann-004). The authors thank Keiko Hongo, Kumiko Muraki, Eri Katsuyama, Takayuki Katsuyama, Haruki Watanabe, Mariko Narazaki, Noriko Tatebe, Yoshinori Matsumoto, Ryutarō Yamanaka, and Kouichi Sugiyama for their great assistance in data management.

Conflict of interest

MH has research grants and/or honoraria from Abbvie Japan Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma, Ltd., and Pfizer Japan Inc. TF has received research grants from Abbvie Japan Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co, Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. HM is a consultant for AbbVie, Astellas and Teijin, receives speaker honoraria

from Astellas, Boehringer-Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Takeda, and Tanabe Mitsubishi, and receives grant support from Astellas, Boehringer-Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, Mochida, MSD, Novartis, Novo Nordisk, Pfizer, Takeda, and Tanabe Mitsubishi.

References

- Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum.* 1990;33(8):1101-7.
- Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum.* 1990;33(8):1094-100.
- Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum.* 1994;37(2):187-92.
- Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis.* 2007;66(2):222-7.
- Group JCSJW. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. *Circ J.* 2011;75(2): 474-503.
- Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Arthritis Res Ther.* 2014;16(2):R101.
- Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). *Clin Exp Nephrol.* 2013;17(5): 619-21.

Supplementary material available online

Supplementary 1-3.

RESEARCH ARTICLE

Open Access



Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study

Ken-ei Sada¹, Masahiro Yamamura², Masayoshi Harigai^{3,4}, Takao Fujii⁵, Yoshinari Takasaki⁶, Koichi Amano⁷, Shouchi Fujimoto⁸, Eri Muso⁹, Yohko Murakawa¹⁰, Yoshihiro Arimura¹¹, Hirofumi Makino^{12*} and for the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan

Abstract

Introduction: This study aims to elucidate the prognosis and the effectiveness of current treatments for Japanese patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).

Methods: Patients with newly diagnosed MPA and GPA were enrolled in a nationwide, prospective, inception cohort study from 22 tertiary Japanese institutions, and treatment patterns and responses were evaluated for 24 months. Primary outcome measures were rates of remission (Birmingham Vasculitis Activity Score, 0) and remission with low-dose glucocorticoids (GC) (prednisolone \leq 10 mg) (GC remission).

Results: Of 156 enrolled patients, 78 MPA patients and 33 GPA patients were included. Concomitant cyclophosphamide (CY) was used in 24 MPA (31 %) and 20 GPA (60 %) patients during the initial 3 weeks of treatment. After 6 months, remission was achieved in 66 MPA (85 %) and 29 GPA (87 %) patients, while GC remission was obtained in only 31 MPA (40 %) and 13 GPA (39 %) patients. During the 24-month period, 14 MPA patients and 2 GPA patients died; end stage renal disease (ESRD) was noted in 13 MPA patients but no GPA patients. Patients with severe disease, according to the European Vasculitis Study Group (EUVAS) classification, showed poorer ESRD-free and overall survival rates than those with generalized disease ($p < 0.0001$). There were no differences in relapse-free survival rates between GPA and MPA, among EUVAS-defined disease severity categories, and between anti-neutrophil cytoplasmic antibody subspecialties.

Conclusions: The majority of Japanese patients with MPA and GPA received treatment with high-dose GC and limited CY use, and showed high remission and relapse-free survival rates but low GC remission rates in clinical practice.

Trial registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000001648. Registered 28 February 2009.

Keywords: Antineutrophil cytoplasmic antibody-associated vasculitis, Cyclophosphamide, Glucocorticoid, Granulomatosis with polyangiitis, Inception cohort, Microscopic polyangiitis, Prospective cohort

* Correspondence: makino@md.okayama-u.ac.jp

¹²Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Full list of author information is available at the end of the article



© 2015 Sada et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by blood vessel inflammation with few or no immune deposits and the presence of ANCA positivity. Recently, the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides classified AAV into four clinically relevant subsets: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and renal-limited AAV (RLV), considered an organ-specific variant of MPA [1]. Watts et al. [2] proposed an epidemiological classification algorithm (the European Medicines Agency (EMA) algorithm), which classifies primary systemic vasculitis into EGPA, GPA, MPA/RLV, and polyarteritis nodosa, with no overlaps between the categories. Significant differences in clinical characteristics and ANCA serology of AAV between European and Asian patients have been suggested [3]. A European epidemiologic study showed a dominance of GPA over MPA [4], while our prospective study [5] and two retrospective studies from China [6] and Japan [3] that applied the EMA algorithm found perinuclear/myeloperoxidase (MPO)-ANCA-positive MPA to be the most common form of AAV in Asia.

The guidelines of the British Society of Rheumatology (BSR) and the European League Against Rheumatism (EULAR) recommended assessment for treatment with high-dose glucocorticoids (GC) and concomitant cyclophosphamide (CY) or rituximab as the first-line option for all patients with newly diagnosed AAV, in principle [7, 8]. These recommendations are based on several randomized controlled trials (RCTs) enrolling more patients with GPA than with MPA [9–11]. Since patients with MPA were older and tended to exhibit higher levels of creatinine than those with GPA in our cohort of Japanese patients [5], these recommendations should be applied to Asian patients with caution in terms of safety.

Recently, Ozaki et al. [12] have reported the treatment effectiveness stratified by disease severity for Japanese patients with MPO-ANCA-positive MPA in a prospective observational study. However, differences in treatment effectiveness between MPA and GPA patients and across the spectrum of disease severity remain to be clarified.

We have previously reported the demographic and baseline clinical characteristics of Japanese patients with AAV who were enrolled in a nationwide, prospective, inception cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated Vasculitides (RemIT-JAV). In the present study, we aimed to elucidate and compare treatment and its effectiveness in terms of remission, survival, and relapse rates in clinical practice in Japanese patients with MPA and GPA using the RemIT-JAV cohort database.

Methods

Settings and patient population

Database

Details regarding the RemIT-JAV study protocol have been reported previously [5]. Twenty-two tertiary care institutions participated in this study and enrolled 156 consecutive patients with newly diagnosed AAV from April 2009 to December 2010. The criteria for enrollment included a diagnosis of AAV made by the site investigators that fulfilled the criteria for primary systemic vasculitis proposed by the EMA algorithm: symptoms and signs characteristic of or compatible with a diagnosis of AAV or polyarteritis nodosa; at least one of histological proof of vasculitis, positive serology for ANCA, specific investigations strongly suggestive of vasculitis and/or granuloma, or eosinophilia; and no other diagnosis to account for symptoms/signs [2]. “Specific investigations” included neurophysiological tests for mononeuritis multiplex, conventional or magnetic resonance angiography, and thoracic or neck magnetic resonance imaging/computed tomography imaging, depending on the signs and symptoms of the patients. The site investigators excluded patients with malignancy, infection, drug-induced vasculitis, secondary vasculitis, other types of vasculitides, vasculitis mimics, sarcoidosis, and other nonvasculitic granulomatous disease. Of the 156 patients enrolled, 78, 33, and 14 were classified as MPA, GPA, and EGPA, respectively. The present study included all patients with MPA or GPA from the RemIT-JAV study, but not those with EGPA. The RemIT-JAV study was conducted according to the Declaration of Helsinki and the ethical guidelines for epidemiologic research in Japan. Written informed consent was obtained from each participant, and the study protocol was approved by the ethics committees at each participating institution (refer to Acknowledgements). The RemIT-JAV study was registered to the University Hospital Medical Information Network Clinical Trials Registry (UMIN000001648).

Data collection

Each patient's baseline data included demographic information, comorbidities, laboratory data, Birmingham Vasculitis Activity Score (BVAS), imaging data, and respiratory function data. Patients were evaluated at 3, 6, 12, 18, and 24 months after diagnosis and at relapse, and the following data were collected: vital status, BVAS, laboratory data, treatments, and adverse events. Organ involvement was defined according to BVAS system. Disease severity was determined by the categorization system developed by the European Vasculitis Study Group (EUVAS) [13]. The Vascular Damage Index (VDI) was also collected at 6, 12, and 24 months. Chest radiography, thoracic computed tomography, arterial blood gas analysis, and respiratory function data were collected at

12 and 24 months in patients with pulmonary involvement. Because the RemIT-JAV study was an observational study, a treatment protocol was not provided. Selection and dosage of immunosuppressants, dosage of GC, and concomitant usage of plasmapheresis were determined at the discretion of the attending physicians. Observation was completed in March 2013, and the baseline characteristics have been described previously [5].

Site investigators filled out the electronic case report forms for each patient and submitted them to the RemIT-JAV data center at the Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Primary and secondary outcomes

The primary effectiveness outcome of the present study was the remission rate. We analyzed two types of remission in this study. The first type of remission was determined systematically by a BVAS of 0 on two occasions at least 1 month apart according to EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis [13]. The second type of remission was defined as BVAS of 0 plus a daily prednisolone (PSL) dose of ≤ 10 mg (designated as “GC remission” hereafter). GCs other than PSL were converted to an equivalent dose of PSL.

Secondary effectiveness outcomes included cumulative overall end-stage renal disease (ESRD)-free and relapse-free survival rates. ESRD was defined as dependence on dialysis or an irreversible increase in serum creatinine level of >5.6 mg/dl (500 μ mol/l). Based on the aforementioned EULAR recommendations, relapse was defined as the reoccurrence or new onset of disease activity attributable to active inflammation. Major relapse was defined as a relapse with organ-threatening or life-threatening disease activity, and other relapses were classified as minor [13].

The safety outcome was the type and incidence of serious infections (SIs). Our definition of SIs was based on an International Conference on Harmonisation report [14]. Bacterial infections that required intravenous antibiotic administration and opportunistic infections were regarded as SIs. The diagnosis of infection was based on the attending physicians’ clinical diagnosis, using a comprehensive evaluation of physical findings, laboratory data, and imaging data.

Statistical analysis

We used baseline and follow-up data at 3, 6, 12, 18, and 24 months from the patients with MPA and GPA enrolled in this study. The cumulative remission, overall survival, ESRD-free survival, and relapse-free survival

rates were analyzed using the Kaplan–Meier method and the log-rank test. $p < 0.05$ was considered significant for statistical analyses between two categories. When comparing three or four categories, statistical significance was determined by $p < 0.05/3$ or $p < 0.05/4$ by Bonferroni correction to avoid multiplicity. When no patients in a group achieved an endpoint, the group was excluded from the long-rank test. As such, the patients with limited type disease, as defined by EUVAS categorization [13], were excluded from the analysis of survival and ESRD-free survival, and patients with early systemic type disease were excluded from the analysis of ESRD-free survival.

All statistical analyses were performed by a biostatistician using the Statistical Package of JMP for Windows software, version 8.0.2 (SAS Institute Inc., Cary, NC, USA).

Results


Patient characteristics

Of the 156 patients with AAV enrolled in the RemIT-JAV study, 78 patients with MPA/RLV and 33 patients with GPA were included in the present study. The mean (median) observation periods were 559 (730) days in MPA patients and 653 (730) days in GPA patients, respectively. At 24 months, 52 patients with MPA and 28 patients with GPA remained in the cohort (Fig. 1). Selected patient characteristics and treatment of these patients are summarized in Table 1; details regarding patient characteristics have been described in our previous report [5].

Treatment patterns

Changes in treatment over time in patients with MPA and GPA are presented in Table 1 as observed data. The mean initial daily PSL dose was 41 mg in MPA patients and 40 mg in GPA patients. Concomitant CY was used during the initial 3 weeks of remission induction therapy in 24 of 78 (31 %) MPA patients and 20 of 33 (60 %) GPA patients. One GPA patient and three MPA patients were treated with plasma exchange. Hemodialysis was implemented at any time point during the initial 3 months in 13 of 78 (14 %) MPA patients and 2 of 33 (6 %) GPA patients. At 3 months, the daily PSL dose was tapered down to ≤ 15 mg in 29 of 67 (43 %) MPA patients and 10 of 32 (31 %) GPA patients.

At 6 months, the mean daily PSL dose was 12 mg in MPA patients and 13 mg in GPA patients, and 10 of 62 MPA patients (16 %) and 8 of 30 GPA patients (27 %) were receiving concomitant azathioprine. Data regarding treatment were not obtained in one patient with MPA. The mean daily PSL dose decreased gradually thereafter in both groups.



Remission

No statistically significant differences in remission rates were found between MPA and GPA patients (Fig. 2a). By 6 months, 66 of 78 MPA patients (85 %) and 29 of 33 GPA patients (87 %) achieved remission, as defined by BVAS of 0 on two occasions at least 1 month apart. However, only 31 of 78 MPA patients (40 %) and 13 of 33 GPA patients (39 %) satisfied the definition of GC remission; that is, BVAS of 0 remission plus a daily PSL dose of ≤ 10 mg.

When both patients with MPA and those with GPA were classified into four different types (i.e. limited, early systemic, generalized, and severe) according to the EUVAS-defined disease severity, there were no significant differences in remission rates across the spectrum of disease severity (Fig. 2b). Remission and GC remission were obtained by 6 months in four (100 %) and three (75 %) of four patients with the limited type, in 18 (90 %) and 10 (50 %) of 20 patients with the early

systemic type, in 58 (89 %) and 24 (37 %) of 65 patients with the generalized type, and in 15 (68 %) and 7 (32 %) of 22 patients with the severe type, respectively.

No significant differences in remission and GC remission rates at 6 months were noted between MPO-ANCA-positive and peroxidase-3 (PR3)-ANCA-positive patients, or between patients with or without interstitial lung disease (ILD).

Overall survival

Sixteen deaths were reported during the observation period (14 MPA patients and two GPA patients). Causes of death reported by site investigators were vasculitis itself (five patients), infection (six patients), and other or unknown (five patients: completely unknown in two patients, cardiac failure in one patient, intracerebral hemorrhage in one patient, and hyperkalemia in one patient). Of the five cases of death caused by vasculitis itself, all patients were treated with GC without

Table 1 Patient characteristics and treatments

	MPA (n = 78)	GPA (n = 33)
Age (years), mean ± SD	71 ± 10	64 ± 13
Sex (male:female)	35:43	12:21
Disease severity, n		
Limited	0	4
Early systemic	15	5
General	47	18
Severe	16	6
MPO-ANCA, n (%)	76 (97)	18 (55)
PR3-ANCA, n (%)	2 (3)	15 (46)
Serum creatinine (mg/dl), mean ± SD	2.46 ± 2.18	1.51 ± 1.32
BVAS, mean ± SD	18 ± 7	20 ± 7
Initial treatments (within 3 weeks)		
Maximum daily dose of PSL (mg/day), mean ± SD	41 ± 15	40 ± 15
mPSL pulse use, n (%)	34 (44)	13 (39)
Cyclophosphamide, n (%)	24 (31)	20 (60)
Oral:intravenous	3:21	7:13
Cumulative dose for 6 months (g), mean ± SD	2.6 ± 2.8	4.3 ± 3.6
Methotrexate, n (%)	0 (0)	2 (6)
Azathioprine, n (%)	0 (0)	0 (0)
Treatments at 6 months		
	n = 62	n = 30
Minimum daily dose of PSL (mg/day), mean ± SD	12 ± 5	13 ± 6
Cyclophosphamide, n	20	16
Methotrexate, n	0	3
Azathioprine, n	10	8
Treatments at 12 months		
	n = 56	n = 28
Minimum daily dose of PSL (mg/day), mean ± SD	9 ± 5	9 ± 6
Cyclophosphamide, n	9	7
Methotrexate, n	0	4
Azathioprine, n	11	11
Treatments at 24 months		
	n = 52	n = 28
Minimum daily dose of PSL (mg/day), mean ± SD	7 ± 5	6 ± 3
Cyclophosphamide, n	4	5
Methotrexate, n	0	4
Azathioprine, n	10	5

ANCA antineutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, mPSL methylprednisolone, PR3 proteinase 3, PSL prednisolone, SD standard deviation

concomitant CY and two patients were treated with plasma exchange. Renal manifestations developed in all five cases and ESRD developed in two of five cases. Lung manifestations developed in four of five patients including pulmonary hemorrhage and ILD in one case, ILD in one case, pleuritis in one case, and pulmonary infiltration in one case.

In terms of overall survival rates, MPA patients tended to have a worse prognosis than GPA patients, although the difference did not reach statistical significance (Fig. 3a; $p = 0.12$). In the spectrum of EUVAS disease severity, there were significant differences in overall survival rates among the four different types (Fig. 3b; $p = 0.0003$). Patients with severe disease, showing the lowest survival rate of 56 % at 24 months, had a markedly poorer prognosis, even compared with those with generalized type disease ($p < 0.0001$).

On the other hand, significant differences in survival rates were undetectable between MPO-ANCA-positive and PR3-ANCA-positive patients (82 % versus 92 % at month 24) or between patients with and without ILD (87 % versus 83 % at month 24).

ESRD-free survival

Thirteen cases of ESRD developed during the observation period in MPA patients, but none occurred in GPA patients. Hence, the ESRD-free survival rate of MPA patients was significantly lower than that of GPA patients, decreasing to 81 % at 24 months (Fig. 4a; $p = 0.012$). In the spectrum of EUVAS disease severity, there were significant differences in ESRD-free survival rates (Fig. 4b; $p < 0.0001$). Patients with severe type disease showed the lowest ESRD-free survival rate of 51 % at 24 months, which was much lower than that of patients with generalized type disease ($p < 0.0001$).

MPO-ANCA-positive patients tended to have lower ESRD-free survival rates than PR3-ANCA-positive patients (84 % versus 100 % at 24 months), although this difference was not statistically significant. No significant difference in ESRD-free survival rates was detectable between patients with and without ILD (90 % versus 85 % at 24 months).

Relapse

Of the 98 patients who achieved remission by 6 months, 23 relapsed during the total observation period, including 18 MPA and five GPA patients, with a mean duration for the remission period of 566 days. Of the 23 relapses, 11 were major relapses and 12 were minor. There were no significant differences in relapse rates between MPA and GPA patients (Fig. 5a; 29 % versus 15 % at month 18) or among patients with the four different types of EUVAS disease severity (Fig. 5b) (0 %, 42 %, 21 %, and 28 % at month 18 for limited, early systemic,




Fig. 2 Cumulative remission rates in MPA and GPA patients and among the four EUVAS-defined disease severity types. **a** Remission rates in MPA and GPA patients. **b** Remission rates among patients with the four types of EUVAS disease severity. BVAS Birmingham Vasculitis Activity Score, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis

generalized, and severe types, respectively). In addition, there were no significant differences in relapse rates between MPO-ANCA-positive and PR3-ANCA-positive patients (25 % versus 21 % at month 18) or between patients with or without ILD (34 % versus 18 % at month 18).

SI and VDI

During the 2-year follow-up period, 76 SIs were reported in 46 patients (41.4 %). The number of SIs decreased over time, from 43 in 27 patients in the first 6 months to 20 in 18 patients in the second 6 months, nine in

seven patients in the third 6 months, and four in four patients in the last 6 months of follow-up. The most frequent site of SI was the respiratory system (41 events), followed by skin and subcutaneous tissue (12 events). Frequently reported types of opportunistic infections were deep mycoses (14 events), cytomegalovirus infection (10 events), and herpes zoster (nine events).

The mean (standard deviation) total VDI score of MPA patients and GPA patients were 1.95 (1.55) and 1.64 (1.57) at 12 months and 2.13 (1.56) and 2.11 (1.79) at 24 months, respectively.




Fig. 3 Cumulative overall survival rates in MPA and GPA patients and among the four EUVAS-defined disease severity types. a Survival rates in MPA and GPA patients. b Survival rates among patients with the four types of EUVAS disease severity. Cumulative survival rates at 24 months are shown at the end of the survival curve for each group. GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis

Discussion

This is the first prospective cohort study comparing the responses of current immunosuppressive therapy in Japanese patients between the two major AAV diseases, MPA and GPA, in clinical practice. In our cohort, the patients had been enrolled from 22 tertiary care institutions in Japan. The majority was positive for MPO-ANCA and diagnosed with MPA, which is in contrast with AAV patients in western countries who are characterized by a predominance of PR3-ANCA and GPA. In addition, although the EULAR recommendations and

the BSR guidelines recommend the concomitant use of CY as induction therapy for severe or generalized AAV [7, 8], concomitant CY was used in only 31 % of MPA patients and 60 % of GPA patients during remission induction, and these rates were apparently lower than those reported in western observational studies (76–82 %) [15–17]. In previous studies, CY was not frequently used in Japan for patients with MPA/RLV, because these patients often present with progressive renal impairment at advanced ages and are thereby considered at high risk for severe infections [15, 18].




Fig. 4 Cumulative ESRD-free survival in MPA and GPA patients and among the four EUVAS-defined disease severity types. **a** ESRD-free survival rates in MPA and GPA patients. **b** ESRD-free survival rates among patients with the four types of EUVAS disease severity. Cumulative ESRD-free survival rates at 24 months are shown at the end of the survival curve for each group. ESRD end-stage renal disease, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis

In this study, we found that remission rates (BVAS of 0 on two occasions at least 1 month apart) at 6 months were 85 % for MPA and 87 % for GPA, whereas GC remission rates (BVAS of 0 plus PSL of ≤ 10 mg/day) were 40 % for MPA and 39 % for GPA. In patients with generalised or severe type diseases, remission rates at month 6 were 84 % for MPA and 83 % for GPA. Time to remission was similar between MPA and GPA patients, and almost all enrolled patients achieved remission at least once during the observation period. These results are

probably comparable with the results reported in RCTs conducted in Europe [19, 20]. In the CYCAZAREM trial [19], 155 patients with generalised GPA and MPA received oral CY and PSL for at least 3 months, and patients who achieved remission by 6 months were assigned to treatment with azathioprine or oral CY. A total of 144 of 155 patients (93 %) achieved remission with a BVAS of 0 by 6 months. In the CYCLOPS trial [20], where 149 patients with generalised GPA and MPA received intravenous pulses of CY or oral CY for at least




Fig. 5 Relapse-free survival in MPA and GPA patients and among the four EUVAS-defined disease severity types. **a** Relapse-free survival rates in MPA and GPA patients. **b** Relapse-free survival rates among patients with the four types of EUVAS disease severity. GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis

3 months, 131 patients (78.9 %) achieved remission by 9 months.

Fourteen of 78 MPA patients and two of 33 GPA patients died during the 24-month observation period. The mortality rate of 14 % in our cohort appears to be slightly higher than the rates found in the European RCTs. For example, eight deaths in 155 patients (5 %) within 18 months and 14 deaths in 149 patients (9 %) within 18 months were reported in the CYCAZAREM and CYCLOPS trials, respectively [19, 20]. This difference

may be partly attributable to the fact that the mean age at the first presentation was higher in our cohort (71 years for MPA and 64 years for GPA) and a higher proportion of patients with EUVAS-defined severe type disease were enrolled in our study (20 %). The latter possibility is supported by the high mortality (35 deaths in 137 patients; 26 %) demonstrated in the MEPEX trial that selectively included severe type MPA and GPA patients. It is intriguing that the MEPEX trial included more than twice as many MPA patients as GPA patients, similar to our study. A

recent comparison of MPA patients between Japan and Europe showed no difference in cumulative patient survival [12, 15]. Thus, these results suggest that MPA may have a worse vital prognosis than GPA, at least in part due to the effects of age at onset.

Further, a marked difference between patients with MPA or GPA in our cohort was found in terms of renal failure. During the observation period, 13 ESRDs occurred in MPA patients, whereas no ESRDs were reported in GPA patients, clearly indicating that ESRD-free survival is much worse with MPA. In agreement with this finding, a retrospective analysis of a large-scale AAV patient database demonstrated that MPO-ANCA-positive patients presented with worse renal function and higher levels of proteinuria, probably due to advanced chronic damage with a smoldering clinical course, than PR3-ANCA-positive patients [21]. Hauer et al. [22] reported that the glomerular filtration rate (GFR) at entry and predominantly chronic renal lesions were potent predictors of the GFR at 18 months in ANCA-associated glomerulonephritis. In the present study, MPA patients had a lower average estimated GFR than GPA patients (38 versus 52 ml/minute/1.73 m²). These data would explain the significant difference in ESRD-free survival between MPA and GPA patients in our cohort.

The relapse rate of 23 % in our cohort was similar to the rate reported recently in China (32.7 %) [23] but was lower than the rates reported previously in western countries (45–76 % at 6 months and 38 % at 1 year) [24, 25]. The higher relapse-free survival rates in our cohort and the Chinese cohort may be related to the predominance of MPO-ANCA positivity in Asian patients with AAV, because MPO-ANCA-positive AAV patients relapse less frequently than PR3-ANCA-positive patients [16]. There is also a possibility that relatively slow tapering of GC contributed to a higher relapse-free survival in this study. Although the British clinical guideline recommends rapid tapering of PSL to 15 mg/day after 3 months of treatment [8], more than half of our patients were still taking ≥ 15 mg/day PSL at month 3. However, it is highly controversial whether fast tapering of GC is associated with increasing risk of relapse in AAV patients. While some studies supported this notion [26, 27], it has recently been demonstrated that GC therapy beyond 6 months is associated with a greater risk of infections, but not with a decreased risk of relapse [24]. The incidence of SIs in the present study was notably higher than those in previous observational studies from European countries [24, 28]. The high incidence of SIs may relate to this slow tapering of GC. On the contrary, VDI scores were comparable with previous RCTs [29].

Our study has several limitations. First, institutional bias should be considered, because this study was performed in university and referral hospitals in Japan.

Because the participating institutions enrolled all patients with newly diagnosed AAV, the selection bias in each institute was low. Second, we could not perform multistratified or multivariate analysis for outcomes because of the small sample size. In addition, we could not perform sufficient comparisons between MPO-ANCA-positive and PR3-ANCA-positive patient groups, because there are few numbers of PR3-ANCA-positive patients in this cohort and the observational period was short. This problem will be solved in the future by combination with another large-scale cohort study of Japanese patients with AAV that is currently ongoing. Third, the 2-year observation period could be too short to evaluate the relapse rates of the disease. Fourth, our effectiveness data may be affected by indication bias because treatments were determined at the discretion of the attending physicians. More sophisticated statistical methods should be employed to overcome this bias with a larger number of patients.

Conclusions

The majority of Japanese patients with MPA and GPA received treatment with high-dose GC and limited CY use, and showed high remission and relapse-free survival rates but low GC remission rates in clinical practice. Further studies are needed to optimize treatment for Japanese patients with AAV, who exhibit different clinical characteristics than patients in western countries in terms of genetic backgrounds, disease categories, and ANCA serology.

Abbreviations

AAV: Antineutrophil cytoplasmic antibody-associated vasculitis; **ANCA:** Antineutrophil cytoplasmic antibody; **BVAS:** Birmingham Vasculitis Activity Score; **CY:** Cyclophosphamide; **EGPA:** Eosinophilic granulomatosis with polyangiitis; **EMA:** European Medicines Agency; **ESRD:** end-stage renal disease; **EULAR:** European League Against Rheumatism; **EUVAS:** European Vasculitis Study Group; **GC:** Glucocorticoids; **GFR:** Glomerular filtration rate; **GPA:** Granulomatosis with polyangiitis; **ILD:** Interstitial lung disease; **MPA:** Microscopic polyangiitis; **MPO:** Myeloperoxidase; **PR3:** Peroxidase-3; **PSL:** Prednisolone; **RCT:** Randomized controlled trial; **RemIT-JAV:** Remission Induction Therapy in Japanese patients with ANCA-associated Vasculitides; **RLV:** renal-limited antineutrophil cytoplasmic antibody-associated vasculitis; **SI:** Serious infection; **VDI:** Vascular Damage Index.

Competing interests

MH has received research grants from Teijin Pharma, Ltd and received research grants and/or honoraria from Abbott Japan Co., Ltd, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Teijin Pharma, Ltd, and Pfizer Japan Inc. **TF** has received research grants from Abbott Japan Co., Ltd, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Pharmaceutical Co. Ltd, Eisai Co., Ltd, Mitsubishi Tanabe Pharma Co., Takeda Pharmaceutical Co., Ltd, and Pfizer Japan Inc. **YT** has received research grants from Asahi Kasei Pharma Co., Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Pharmaceutical Co. Ltd, Eisai Co., Ltd, Mitsubishi Tanabe Pharma Co., MSD K.K., and Santen Pharmaceutical Co., Ltd. **KA** has received research grants from Astellas Pharma Inc. and Chugai Pharmaceutical Co. Ltd, and received honoraria from AbbVie Inc., Astellas Pharm Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharm Co., and

Pfizer Japan Inc. YM has received research grants from Japan Blood Products Org., Taisho Toyama Pharmaceutical Co., Ltd, and Nippon Kayaku Co., Ltd; received honoraria from Takeda Pharmaceutical Co., Ltd, AbbVie Inc., Janssen Pharmaceutical K.K., and UCB Japan Co., Ltd; and received research grants and honoraria from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Co., Teijin Pharma, Ltd, and Eisai Co., Ltd. HM is a consultant for AbbVie, Astellas, and Teijin; receives speaker honoraria from Astellas, Boehringer-Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Takeda, and Tanabe Mitsubishi; and receives grant support from Astellas, Boehringer-Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, Mochida, MSD, Novartis, Novo Nordisk, Pfizer, Takeda, and Tanabe Mitsubishi. The remaining authors state that they have no competing interests.

Authors' contributions

KS was responsible for conception and design, data collection and analysis, and manuscript writing. MY was responsible for conception and design, data collection and analysis, and critical revision. MH was responsible for conception and design, data collection and analysis, and critical revision. TF was responsible for conception and design, data collection and analysis, and critical revision. YT was responsible for data collection and interpretation, and critical revision. KA was responsible for data collection and interpretation, and critical revision. SF was responsible for data collection and interpretation and critical revision. EM was responsible for data collection and interpretation and critical revision. YM was responsible for data collection and interpretation and critical revision. YA was responsible for conception and design, data collection and analysis, and critical revision. HM was responsible for conception and design, data collection and analysis, and critical revision. All authors read and approved the final manuscript.

Authors' information

Research Committee of Intractable Vasculitides of the Ministry of Health, Labour, and Welfare of Japan – in addition to the authors, the following investigators and institutions participated in this study: Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University (Hiroaki Dobashi); Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine (Hidehiro Yamada); Department of Nephrology (Kunihiro Yamagata) and Division of Internal Medicine (Satoshi Ito), Faculty of Medicine, University of Tsukuba; Department of Respiratory Medicine, Toho University Omori Medical Center (Sakae Homma); Division of Nephrology, Department of Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Medicine, Kanazawa University (Takashi Wada); Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine (Shunichi Kumagai); Department of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo (Junichi Hirahashi); Division of Rheumatology, Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Science (Shogo Banno); Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine (Hitoshi Hasegawa); Division of Nephrology, Department of Internal Medicine, Jichi Medical University (Wako Yumura); Division of Nephrology, Department of Internal Medicine, Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine (Hiroaki Matsubara); Division of Nephrology, Tokyo Medical University Hachioji Medical Center (Masaharu Yoshida); Department of Dermatology, Kitasato University School of Medicine (Kensei Katsuoka); and Third Department of Internal Medicine, Division of Immunology and Rheumatology, Hamamatsu University School of Medicine, Hamamatsu (Noriyoshi Ogawa).

Acknowledgements

This work was supported by grants from Research on Rare and Intractable Diseases, the Ministry of Health, Labour and Welfare, Japan (nannti-ippann-004) and the study group for strategic exploration of drug seeds for ANCA-associated vasculitis and construction of clinical evidence from Japan Agency for Medical Research and development, AMED.

The authors thank Keiko Hongo, Kumiko Muraki, Eri Katsuyama, Takayuki Katsuyama, Haruki Watanabe, Mariko Narazaki, Noriko Toyota, Yoshinori Matsumoto, Ryutaro Yamanaka, and Kouichi Sugiyama for their great assistance in data management.

This study was approved by the following ethical committees: Ethics Committee of the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; Medical Research Ethics Committee of Tokyo Medical and Dental University; Kyoto University Ethics Committee Review Board; Ethics Committee of Kagawa University; Ethics Committee of Juntendo University School of Medicine; Ethics Committee University of Tsukuba Hospital; Ethics Committee of St. Marianna University School of Medicine; Kanazawa University Ethical Committee; Ethics Committee of the University of Tokyo; Ethics Committee of Kyorin University School of Medicine; Saitama Medical Center Hospital Ethics Committee; Research Ethics Committee of the University of Miyazaki; local ethics committee of Toho University; Ethics Committee of Kobe University Hospital; Ethics Committee of Kitano Hospital, The Tazuke Kofukai Medical Research Institute; Shimane University Institutional Committee on Ethics; Ethics Review Committee of Nagoya City University Graduate School of Medical Sciences; Ethics Committee of Ehime University Hospital; Ethics Committee of Jichi Medical University; Ethics Committee of Kyoto Prefectural University School of Medicine; Ethics Committee of Tokyo Medical University Hachioji Medical Center; Ethics Committee of Kitasato University Hospital; and Ethics Committee of Hamamatsu University School of Medicine.

Author details

¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. ²Center for Rheumatology, Okayama Saiseikai General Hospital, 1-17-18 Ifuku-cho, Kita-ku, Okayama 700-8511, Japan. ³Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. ⁴Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. ⁵Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. ⁶Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. ⁷Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Saitama 350-8550, Japan. ⁸Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, 5200 Kiyotakecho Kihara, Miyazaki 889-1692, Japan. ⁹Center for Nephrology and Urology, Division of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute, 2-4-20 Ohgimachi, Osaka 530-8480, Japan. ¹⁰Department of Rheumatology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo 693-8501, Japan. ¹¹Nephrology and Rheumatology, First Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan. ¹²Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.

Received: 29 April 2015 Accepted: 9 October 2015

Published online: 02 November 2015

References

- Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* 2013;65:1–11.
- Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis.* 2007;66:222–7.
- Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. *Rheumatology (Oxford).* 2011;50:1916–20.
- Watts RA, Lane SE, Benthall G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. *Arthritis Rheum.* 2000;43:414–9.
- Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Arthritis Res Ther.* 2014;16:R101.

6. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. *Rheumatology (Oxford)*. 2008;47:708–12.
7. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis*. 2009;68:310–7.
8. Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHRP guideline for the management of adults with ANCA-associated vasculitis. *Rheumatology (Oxford)*. 2014.
9. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. *Nephrol Dial Transplant*. 1991;6:531–5.
10. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. *QJM*. 1997;90:401–9.
11. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. *Arthritis Rheum*. 1997;40:2187–98.
12. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. *Mod Rheumatol*. 2012;22:394–404.
13. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. *Ann Rheum Dis*. 2007;66:605–17.
14. ICH Steering Committee. ICH harmonized tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting; 1994.
15. Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. *J Rheumatol*. 2014;41:325–33.
16. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. *Arthritis Rheum*. 2012;64:3452–62.
17. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. *Arthritis Rheum*. 2008;58:2908–18.
18. Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. *Clin Exp Nephrol*. 2013;17:51–8.
19. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med*. 2003;349:36–44.
20. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med*. 2009;150:670–80.
21. de Jooode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. *Clin J Am Soc Nephrol*. 2013;8:1709–17.
22. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. *Kidney Int*. 2002;62:1732–42.
23. Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in ANCA-associated vasculitis: a study of 439 cases in a single Chinese center. *Arthritis Rheumatol*. 2014;66:1920–6.
24. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. *Clin J Am Soc Nephrol*. 2012;7:240–7.
25. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2012;64:542–8.
26. Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. *J Rheumatol*. 2012;39:545–51.
27. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. *Arthritis Care Res (Hoboken)*. 2010;62:1166–73.
28. Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. *Ann Rheum Dis*. 2009;68:658–63.
29. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. *Ann Rheum Dis*. 2015;74:177–84.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

